Jubilant Pharmova Limited announced the outcome of its postal ballot process regarding the issuance of Non-Convertible Debentures (NCDs) on a private placement basis.
Key Resolution and Outcome
The special resolution for "Approval for Issuance of Non-Convertible Debentures on a Private Placement Basis" was duly passed by shareholders with the requisite majority. The resolution was deemed passed on November 20, 2026, being the last date specified for remote e-voting.
Voting Results Details
Overall Voting Results:
- Total valid votes received: 126,660,315
- Number of shareholders who voted: 393
- Votes in favor: 125,887,158 (99.39%)
- Votes against: 773,157 (0.61%)
Category-wise Voting Breakdown:
Promoter and Promoter Group:
- Shares held: 75,938,622
- Votes polled: 75,938,622 (100.00% of shares held)
- Votes in favor: 75,938,622 (100.00%)
- Votes against: 0 (0.00%)
Public Institutions:
- Shares held: 47,230,619
- Votes polled: 40,426,055 (85.5928% of shares held)
- Votes in favor: 39,653,808 (98.0897%)
- Votes against: 772,247 (1.9102%)
Public Non-Institutions:
- Shares held: 36,111,898
- Votes polled: 10,295,638 (28.5103% of shares held)
- Votes in favor: 10,294,728 (99.9911%)
- Votes against: 910 (0.0088%)
Total Shareholding and Voting:
- Total shares outstanding: 159,281,139
- Total votes polled: 126,660,315 (79.5199% of outstanding shares)
- Total votes in favor: 125,887,158 (99.3895% of votes polled)
- Total votes against: 773,157 (0.6104% of votes polled)
Process and Timeline
- Cut-off date for shareholder eligibility: October 9, 2026
- Postal Ballot Notice dated: October 21, 2026
- Remote e-voting period: October 22, 2026 (9:00 AM) to November 20, 2026 (5:00 PM)
- Scrutinizer's Report dated: November 20, 2026
- Scrutinizer: Rupinder Singh Bhatia, Practicing Company Secretary (CP No.: 2514)
- The promoter/promoter group was not interested in the resolution
Documentation
The disclosure includes the voting results in prescribed format and the Scrutinizer's Report, which are also available on the company's website (www.jubilantpharmova.com) and NSDL's website.
Financial Impact
The disclosure does not quantify the financial impact, size, or terms of the proposed Non-Convertible Debenture issuance.